Balanced news tone
News Sentiment
BLCO sentiment intelligence
Bausch + Lomb Corporation news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
83/100 classification confidence.
directly relevant articles
high-authority source matches
-6.8% over one week, +8.5% over four weeks, trend inactive, and near fair-value range.
How Investors May Respond To Bausch + Lomb (BLCO) Expanding Ophthalmic Tools With EyeGility And Orphia AI
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
How Investors May Respond To Bausch + Lomb (BLCO) Expanding Ophthalmic Tools With EyeGility And Orphia AI
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jul 2026 22:03
- Source
- simplywall.st
Bausch + Lomb Corporation (BLCO) Stock Analysis: Examining a Healthcare Leader with 11.68% Potential Upside
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 13 Jul 2026 09:23
- Source
- DirectorsTalk Interviews
Why Bausch + Lomb (BLCO) Stock Is Trading Lower Today
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 10 Jul 2026 21:27
- Source
- Market source
BLCO Stock Drops After-Hours — Bausch + Lomb Halts Glaucoma Eye Drop Program After Trial Failure
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jul 2026 23:13
- Source
- Stocktwits
Bausch + Lomb (BLCO) Could Be 57% Below Fair Value After Product Updates
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jul 2026 07:00
- Source
- Market source
Bausch + Lomb sets July 29 call for Q2 2026 results
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 06 Jul 2026 07:00
- Source
- Stock Titan
Medical Devices & Supplies - Specialty Stocks Q1 Teardown: Bausch + Lomb (NYSE:BLCO) Vs The Rest
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 May 2026 07:00
- Source
- Market source
Bausch & Lomb Earnings: Vision Care Resilience and Pharmaceutical Rebound Lead Off 2026
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 04 May 2026 07:00
- Source
- Morningstar
Bausch + Lomb (BLCO) Surpasses Q1 Earnings and Revenue Estimates
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Apr 2026 07:00
- Source
- Market source
Bausch + Lomb (NYSE:BLCO) Posts Better-Than-Expected Sales In Q1 CY2026
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Apr 2026 07:00
- Source
- StockStory
Bausch + Lomb (BLCO) Q1 Earnings Report Preview: What To Look For
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 28 Apr 2026 07:00
- Source
- Market source
Is It Time To Reconsider Bausch + Lomb (BLCO) After Its 28% One-Year Rally?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Apr 2026 07:00
- Source
- Market source
Why Bausch + Lomb (BLCO) Just Strengthened Something Beyond Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
Bausch + Lomb brings full-range vision lens implant to Europe
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Apr 2026 07:00
- Source
- Stock Titan
Is It Time To Reconsider Bausch + Lomb (BLCO) After Recent Share Price Weakness
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Mar 2026 07:00
- Source
- Market source
Bausch + Lomb (BLCO) Reports Record Q4 2025 Financial Results Driven by Strong Pharmaceutical and Vision Care Growth
- Tone
- Positive 95/100
- Event
- Earnings
- Published
- 27 Feb 2026 08:00
- Source
- Finviz
Bausch & Lomb Earnings: Nice Results from Growth Momentum, Solid Execution, and Pipeline Investment
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 18 Feb 2026 08:00
- Source
- Morningstar
After M&A rumors sparked stock volatility, Bausch + Lomb confirms it's exploring a sale
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Dec 2024 08:00
- Source
- Fierce Pharma
Bausch + Lomb Responds to Rumors of a Potential Sale
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Dec 2024 08:00
- Source
- BioSpace
Op-ed: Here’s why a sale of Bausch + Lomb could lead to a windfall for Bausch Health investors
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Sep 2024 07:00
- Source
- CNBC
Laval-based pharmaceutical company Bausch + Lomb plans US$788-million IPO
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 May 2022 07:00
- Source
- The Globe and Mail
Canadian company to buy Bausch + Lomb for $8.7B
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 27 May 2013 07:00
- Source
- NBC News